China's Sinovac Just Steps Away From Crossing Global Finish Line In Race To Launch A/H1N1 Vaccine
This article was originally published in PharmAsia News
Executive Summary
BEIJING - Just days away from widely expected regulatory approval for an A/H1N1 vaccine, the Beijing-based Sinovac Biotech is now virtually guaranteed to become the first producer in the world to market a defense to the swine flu pandemic
You may also be interested in...
Chinese Regulators Report Steady Progress In Promoting Innovation - DIA China Conference
BEIJING - China's State FDA has made steady progress in meeting the challenges of drug supervision while at the same time encouraging innovation and ensuring safety, SFDA Deputy Commissioner Wu Zhen told executives and scientists during the second Drug Information Association China annual meeting in Beijing this week
Chinese Regulators Report Steady Progress In Promoting Innovation - DIA China Conference
BEIJING - China's State FDA has made steady progress in meeting the challenges of drug supervision while at the same time encouraging innovation and ensuring safety, SFDA Deputy Commissioner Wu Zhen told executives and scientists during the second Drug Information Association China annual meeting in Beijing this week
Korea FDA Evaluating H1N1 Vaccine Applications from GSK and Three Korean Pharmas
SEOUL - Korea FDA said it is evaluating three applications for the A/H1N1 flu vaccine submitted by GlaxoSmithKline and Korean companies Green Cross, Boryung Pharmaceutical and Hanwha Pharma